Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5074744
Max Phase: Preclinical
Molecular Formula: C65H92F2N10O10
Molecular Weight: 1211.51
Molecule Type: Unknown
Associated Items:
ID: ALA5074744
Max Phase: Preclinical
Molecular Formula: C65H92F2N10O10
Molecular Weight: 1211.51
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC(C)c1nnc(CCNC(=O)COCC(=O)NCCCCCCCNC(=O)COCC(=O)N[C@@H]2CC[C@@]3(O)[C@H]4Cc5ccc(O)c6c5[C@@]3(CCN4CC3CC3)[C@H]2O6)n1C1C[C@H]2CC[C@@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1
Standard InChI: InChI=1S/C65H92F2N10O10/c1-41(2)61-74-73-53(77(61)48-34-46-16-17-47(35-48)76(46)31-23-49(43-11-7-6-8-12-43)72-62(83)44-19-24-63(66,67)25-20-44)22-30-70-56(81)39-85-37-54(79)68-28-9-4-3-5-10-29-69-55(80)38-86-40-57(82)71-50-21-26-65(84)52-33-45-15-18-51(78)59-58(45)64(65,60(50)87-59)27-32-75(52)36-42-13-14-42/h6-8,11-12,15,18,41-42,44,46-50,52,60,78,84H,3-5,9-10,13-14,16-17,19-40H2,1-2H3,(H,68,79)(H,69,80)(H,70,81)(H,71,82)(H,72,83)/t46-,47+,48?,49-,50+,52+,60-,64-,65+/m0/s1
Standard InChI Key: RJZAGAMHLSCKAW-FIHPGCAYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1211.51 | Molecular Weight (Monoisotopic): 1210.6966 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Huang B, Wang H, Zheng Y, Li M, Kang G, Barreto-de-Souza V, Nassehi N, Knapp PE, Selley DE, Hauser KF, Zhang Y.. (2021) Structure-Based Design and Development of Chemical Probes Targeting Putative MOR-CCR5 Heterodimers to Inhibit Opioid Exacerbated HIV-1 Infectivity., 64 (11.0): [PMID:34027668] [10.1021/acs.jmedchem.1c00408] |
Source(1):